130475-07-9 Usage
Uses
Used in Pharmaceutical Synthesis:
1-(4,5-Dichloro-2-nitrophenyl)piperidine is used as an intermediate in the synthesis of pharmaceutical compounds. Its chemical structure makes it a valuable building block for the development of new drugs targeting various biological pathways, particularly in the field of neuroscience and drug discovery.
Used in Agrochemical Synthesis:
In addition to its pharmaceutical applications, 1-(4,5-Dichloro-2-nitrophenyl)piperidine is also utilized as an intermediate in the synthesis of agrochemical compounds. Its unique chemical properties allow for the creation of new agrochemicals that can address various agricultural needs.
Proper handling and disposal procedures should be followed when working with 1-(4,5-Dichloro-2-nitrophenyl)piperidine to ensure safety and environmental responsibility.
Check Digit Verification of cas no
The CAS Registry Mumber 130475-07-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,3,0,4,7 and 5 respectively; the second part has 2 digits, 0 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 130475-07:
(8*1)+(7*3)+(6*0)+(5*4)+(4*7)+(3*5)+(2*0)+(1*7)=99
99 % 10 = 9
So 130475-07-9 is a valid CAS Registry Number.
130475-07-9Relevant articles and documents
AROMATIC AMIDES AS INHIBITORS OF C-FMS KINASE
-
Page/Page column 46, (2008/06/13)
The invention relates to compounds of Formula (I), wherein A, X, R2 and W are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, colon cancer, stomach cancer, hairy cell leukemia and non-small lung carcinoma; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, Paget's disease, and other diseases in which bone resorption mediates morbidity including arthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of Formula (I), are also provided.
